Welcome to our dedicated page for INSMED SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
SCHAFER CAROL reported acquisition or exercise transactions in this Form 4 filing.
INSMED Inc director Carol Schafer received an equity award of 3,305 Restricted Stock Units (RSUs) on May 13, 2026. Each RSU represents a contingent right to receive one share of common stock, granted for no cash consideration as part of director compensation.
The RSUs vest in full on the first anniversary of the grant date if she remains on the Board through the earlier of that date or the company’s annual shareholder meeting in that year, and attends at least 75% of Board meetings during the period. After this grant, she holds 66,622 shares of common stock directly.
INSMED Inc Chief Operating Officer Roger Adsett reported a small share sale primarily tied to taxes on equity compensation. He sold 5,837 shares of common stock at an average price of $116.18 per share. A footnote explains the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees, rather than as a discretionary portfolio move. After the transaction, he directly holds 100,973 shares of INSMED common stock.
ANDERSON ELIZABETH M reported acquisition or exercise transactions in this Form 4 filing.
INSMED Inc director Elizabeth M. Anderson received a grant of 3,305 Restricted Stock Units (RSUs), each representing one share of common stock. The award was granted for no cash consideration.
The RSUs vest in full on the first anniversary of the May 13, 2026 grant date if she remains on the Board and attends at least 75% of Board meetings. Following the grant, she directly holds 62,034 shares.
INSMED Inc Chief Medical Officer Martina Flammer sold 18,333 shares of common stock in open-market transactions. The sales occurred on May 13 and May 14, 2026 at prices around $112.76 to $117.54 per share. After these trades, she directly holds 64,910 shares. Footnotes explain that shares were sold to satisfy tax withholding obligations on vested Restricted Stock Units and that the transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
INSMED Inc Chief Legal Officer Michael Alexander Smith reported an open-market sale of 4,109 shares of common stock at an average price of $116.18 per share. According to the filing, the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Following this tax-related sale, Smith directly holds 47,762 shares of INSMED common stock.
SHAROKY MELVIN MD reported acquisition or exercise transactions in this Form 4 filing.
INSMED Inc director Melvin Sharoky received 3,305 Restricted Stock Units (RSUs) of Common Stock as a grant. The RSUs were granted on May 13, 2026 for no cash consideration and vest in full on the first anniversary of the grant date, subject to continued Board service and meeting-attendance conditions.
After this grant, Sharoky directly holds 246,081 shares of Common Stock, in addition to several indirect holdings through custodial UTMA/FL accounts, an LLC, and his spouse.
Brennan David R reported acquisition or exercise transactions in this Form 4 filing.
INSMED Inc director David R. Brennan reported new equity compensation and existing indirect holdings. He received 3,305 Restricted Stock Units (RSUs), each representing one share of common stock, granted on May 13, 2026 for no consideration. These RSUs vest in full on the first anniversary of the grant date if he remains on the Board and attends at least 75% of Board meetings during the vesting period. After the grant, he directly holds 64,238 shares of common stock and has an additional 60,000 shares held indirectly through his spouse’s revocable trust.
Desjardins Clarissa reported acquisition or exercise transactions in this Form 4 filing.
INSMED Inc director Clarissa Desjardins reported a new equity award and updated holdings. She received a grant of 3,305 Restricted Stock Units (RSUs) of Common Stock on May 13, 2026 for no cash consideration. After this grant, she holds 70,312 shares of Common Stock directly and 3,025 shares indirectly through her spouse.
The RSUs represent a contingent right to receive one share of Common Stock each and vest in full on the first anniversary of the grant date. Vesting requires that she remain on the Board through the earlier of that anniversary or the company’s annual shareholder meeting in that year and attend at least 75% of Board meetings during the vesting period.
LEE LEO reported acquisition or exercise transactions in this Form 4 filing.
Insmed Inc director Leo Lee reported receiving a grant of 3,305 shares of Common Stock in the form of Restricted Stock Units (RSUs) on May 13, 2026 for no cash consideration. Each RSU represents a contingent right to one share and vests in full on the first anniversary of the grant date if he remains on the Board through the earlier of that date or the company’s Annual Shareholder Meeting in that year, and attends at least 75% of Board meetings during the period. After this grant and an 11‑share downward correction for a prior clerical error, Lee beneficially owns 57,971 shares directly.
INSMED Inc Chair and CEO William Lewis reported an insider transaction involving company Common Stock. On May 13, 2026, he sold 13,283 shares at $116.18 per share, with a footnote explaining the shares were sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and related broker fees.
Following this sale, Lewis held 287,902 shares of Common Stock directly and 233,924 shares indirectly through a trust, indicating he retains a substantial equity stake in INSMED after these tax-related transactions.